Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

被引:134
|
作者
Rodina, Anna
Vilenchik, Maria
Moulick, Kamalika
Aguirre, Julia
Kim, Joungnam
Chiang, Anne
Litz, Julie
Clement, Cristina C.
Kang, Yanlong
She, Yuhong
Wu, Nian
Felts, Sara
Wipf, Peter
Massague, Joan
Jiang, Xuejun
Brodsky, Jeffrey L.
Krystal, Geoffrey W.
Chiosis, Gabriela
机构
[1] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA
[3] Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23249 USA
[4] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[5] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA
[6] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA
[7] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA
关键词
D O I
10.1038/nchembio.2007.10
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The heat shock protein 90 (Hsp90) has a critical role in malignant transformation. Whereas its ability to maintain the functional conformations of mutant and aberrant oncoproteins is established, a transformation-specific regulation of the antiapoptotic phenotype by Hsp90 is poorly understood. By using selective compounds, we have discovered that small-cell lung carcinoma is a distinctive cellular system in which apoptosis is mainly regulated by Hsp90. Unlike the well-characterized antiapoptotic chaperone Hsp70, Hsp90 is not a general inhibitor of apoptosis, but it assumes this role in systems such as small-cell lung carcinoma, in which apoptosis is uniquely dependent on and effected through the intrinsic pathway, without involvement of caspase elements upstream of mitochondria or alternate pathways that are not apoptosome-channeled. These results provide important evidence for a transformation-specific interplay between chaperones in regulating apoptosis in malignant cells.
引用
收藏
页码:498 / 507
页数:10
相关论文
共 50 条
  • [1] Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
    Anna Rodina
    Maria Vilenchik
    Kamalika Moulick
    Julia Aguirre
    Joungnam Kim
    Anne Chiang
    Julie Litz
    Cristina C Clement
    Yanlong Kang
    Yuhong She
    Nian Wu
    Sara Felts
    Peter Wipf
    Joan Massague
    Xuejun Jiang
    Jeffrey L Brodsky
    Geoffrey W Krystal
    Gabriela Chiosis
    Nature Chemical Biology, 2007, 3 : 498 - 507
  • [2] Defining Hsp90 as inhibitor of apoptosis in small cell lung cancer
    Chiosis, G.
    Rodina, A.
    Kim, J.
    Aguirre, J.
    Moulick, K.
    Lopes, E. Caldas
    Wu, N.
    She, Y.
    EJC SUPPLEMENTS, 2006, 4 (12): : 128 - 128
  • [3] Effect of HSP90 inhibitor ganetespib on sternness in small cell lung cancer
    Gomez-Casal, Roberto
    Zhang, Peng
    Wang, Hong
    Gardner, Paul
    Herman, James
    Levina, Vera
    CANCER RESEARCH, 2016, 76
  • [4] Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer
    Paul Workman
    Marissa V Powers
    Nature Chemical Biology, 2007, 3 : 455 - 457
  • [5] Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer
    Workman, Paul
    Powers, Marissa V.
    NATURE CHEMICAL BIOLOGY, 2007, 3 (08) : 455 - 457
  • [6] Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer
    Restall, Ian J.
    Lorimer, Ian A. J.
    PLOS ONE, 2010, 5 (06):
  • [7] Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
    Acquaviva, Jaime
    Smith, Donald L.
    Sang, Jim
    Friedland, Julie C.
    He, Suqin
    Sequeira, Manuel
    Zhang, Chaohua
    Wada, Yumiko
    Proia, David A.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) : 2633 - 2643
  • [8] Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A. Proia
    Jim Sang
    Suqin He
    Donald L. Smith
    Manuel Sequeira
    Chaohua Zhang
    Yuan Liu
    Shuxia Ye
    Dan Zhou
    Ronald K. Blackman
    Kevin P. Foley
    Keizo Koya
    Yumiko Wada
    Investigational New Drugs, 2012, 30 : 2201 - 2209
  • [9] Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    Proia, David A.
    Sang, Jim
    He, Suqin
    Smith, Donald L.
    Sequeira, Manuel
    Zhang, Chaohua
    Liu, Yuan
    Ye, Shuxia
    Zhou, Dan
    Blackman, Ronald K.
    Foley, Kevin P.
    Koya, Keizo
    Wada, Yumiko
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2201 - 2209
  • [10] HSP90 as a novel molecular target in non-small-cell lung cancer
    Esfahani, Khashayar
    Cohen, Victor
    LUNG CANCER-TARGETS AND THERAPY, 2016, 7 : 11 - 17